About us
Discover Masinova’s mission, values, and development philosophy—built on QbD, SOP-driven execution, and decision-quality data. Learn how we de-risk programs and accelerate translation from discovery through preclinical development and Phase I readiness, with details available under NDA.
Our mission
Masinova’s mission is to translate rigorous, reproducible science into safe, effective therapies—advancing programs efficiently from discovery through preclinical development and into Phase I clinical testing. We apply Quality-by-Design (QbD) principles to strengthen reproducibility, integrate safety early, and enable disciplined, decision-driven translation.
Our values
Our approach to drug development is defined by three core values:
Rigor & Reproducibility
We apply disciplined experimental design, SOP-driven execution, and high-quality data standards to generate repeatable, decision-ready evidence.
Safety-by-Design
We integrate safety and risk assessment early—building programs with a clear path to IND-enabling requirements and first-in-human readiness.
Efficient Translation
We use milestone-based planning and defined go/no-go criteria to move programs efficiently from discovery through preclinical development and into Phase I.
Founder CEO
Masinova is founded and led by Mandana Daraei Fathabad, Founder & CEO. Mandana brings a rigor-led, Quality-by-Design (QbD) approach to therapeutic R&D—translating precise research into development-ready programs built for reproducibility, early safety integration, and efficient progression from preclinical milestones toward Phase I.
"Masinova is committed to raising the standard for reproducible, Quality-by-Design drug development."
The Masinova Team